Biomedicines (Mar 2023)

COVID-19 Associated Vasculitis Confirmed by the Tissues RT-PCR: A Case Series Report

  • Konstantin E. Belozerov,
  • Ilia S. Avrusin,
  • Lyubov I. Andaryanova,
  • Anna M. Guseva,
  • Zaira S. Shogenova,
  • Irina N. Belanovich,
  • Anna V. Lobacheva,
  • Tatiana L. Kornishina,
  • Eugenia A. Isupova,
  • Vera V. Masalova,
  • Olga V. Kalashnikova,
  • Andrey V. Nokhrin,
  • Tatyana F. Panova,
  • Yulia P. Dutova,
  • Svetlana L. Myshkovskaya,
  • Kirill Y. Kostyunin,
  • Andrey B. Komissarov,
  • Vyacheslav G. Chasnyk,
  • Liudmila V. Bregel,
  • Mikhail M. Kostik

DOI
https://doi.org/10.3390/biomedicines11030870
Journal volume & issue
Vol. 11, no. 3
p. 870

Abstract

Read online

Background: Several cases of skin and central nervous system vasculopathy associated with COVID-19 in children have been published, but the information is rather limited. Our study aimed to describe these cases of vasculitis associated with COVID-19 in children. Methods: In the retrospective-prospective case series study we included information regarding four children with COVID-19-associated vasculitis. In every case, we had a morphological description and the etiology was confirmed via real-time polymerase chain reaction during a tissue biopsy. Results: The most involved systems were skin (4/4), respiratory (3/4), cardiovascular (2/4), nervous (1/4), eye (1/4), kidney (1/4), and inner year (1/4). All patients had increased inflammatory markers and thrombotic parameters (D-dimer). No patient met the criteria for multisystem inflammatory syndrome in children. Two patients met polyarteritis nodosa criteria, one met Henoch–Schonlein purpura criteria, and one met unclassified vasculitis criteria. All patients were treated with systemic glucocorticosteroids (two-pulse therapy). Non-biologic DMARDs were prescribed in all cases; 1/4 patients (25%) was treated with intravenous immunoglobuline, and 3/4 (75%) were treated with biologics (etanercept, tocilizumab, and adalimumab). Conclusions: Vasculitis associated with COVID-19 could be a life-threatening condition; SARS-CoV-2 might be a new trigger or etiological agent for vasculitis and other immune-mediated diseases. Further research and collection of similar cases are required.

Keywords